RNATICS GmbH, a pioneering biotech company located near Munich, is pleased to announce that Prof. Dr. Thomas Thum has joined the company’s board. His appointment marks a significant milestone in accelerating the company’s mission to develop targeted RNA therapies for inflammatory lung diseases and reflects RNATICS’ commitment to translating groundbreaking research into life-changing treatments.
With more than 20 years of pioneering experience in RNA therapeutics and as co-founder of Cardior Pharmaceuticals GmbH, Prof. Thum has been at the forefront of RNA-based advances. In addition to leading the Institute for Molecular and Translational Therapeutic Strategies at the Hannover Medical School, where his work focuses on harnessing microRNAs to promote tissue regeneration and repair, Prof. Thum has consistently translated cutting-edge research into clinical success. His strategic insight and track record will be instrumental as RNATICS advances its programs and expands its targeted therapy portfolio.
At the core of RNATICS’ breakthrough is its revolutionary carbohydrate coupling technology, which enables the precise delivery of RNA therapeutics directly to lung macrophages. This novel approach offers the potential for targeted intervention in a variety of inflammatory lung diseases. “This cell-specific targeting is a game changer for the treatment of inflammatory lung diseases,” said Dr. Johannes Schmidt, CEO of RNATICS. “We are pleased to welcome Prof. Thum’s expertise as we advance our lead candidate, RCS-21, and further expand the application potential of our RNA delivery platform.”
We are pleased to welcome Prof. Thum's expertise as we advance RCS-21 in the clinic.
Dr. Johannes Schmidt, CEO of RNATICS
Prof. Thum commented, “I am excited to join such a dynamic and visionary team. The promise of targeted RNA delivery through state-of-the-art ligand coupling is immense and I look forward to contributing to RNATICS’ success. I am particularly impressed by the company’s strong foundation, rooted in academic excellence at TUM and cutting-edge biotechnology, which positions RNATICS at the forefront of precision medicine.”
The promise of targeted RNA delivery through state-of-the-art ligand coupling is immense.
Prof. Dr. Thomas Thum